SINT vs. NMRD, BJDX, MOTS, OSAP, RSLS, DYNT, INVO, QNRX, TNON, and IONM
Should you be buying Sintx Technologies stock or one of its competitors? The main competitors of Sintx Technologies include Nemaura Medical (NMRD), Bluejay Diagnostics (BJDX), Motus GI (MOTS), ProSomnus (OSAP), ReShape Lifesciences (RSLS), Dynatronics (DYNT), INVO Bioscience (INVO), Quoin Pharmaceuticals (QNRX), Tenon Medical (TNON), and Assure (IONM). These companies are all part of the "surgical & medical instruments" industry.
Sintx Technologies (NASDAQ:SINT) and Nemaura Medical (NASDAQ:NMRD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.
Sintx Technologies has higher revenue and earnings than Nemaura Medical. Nemaura Medical is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.
18.4% of Sintx Technologies shares are held by institutional investors. Comparatively, 4.4% of Nemaura Medical shares are held by institutional investors. 0.8% of Sintx Technologies shares are held by company insiders. Comparatively, 41.6% of Nemaura Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Nemaura Medical has a net margin of 0.00% compared to Sintx Technologies' net margin of -318.99%. Nemaura Medical's return on equity of 0.00% beat Sintx Technologies' return on equity.
Sintx Technologies received 32 more outperform votes than Nemaura Medical when rated by MarketBeat users. Likewise, 61.02% of users gave Sintx Technologies an outperform vote while only 57.14% of users gave Nemaura Medical an outperform vote.
In the previous week, Sintx Technologies had 5 more articles in the media than Nemaura Medical. MarketBeat recorded 6 mentions for Sintx Technologies and 1 mentions for Nemaura Medical. Sintx Technologies' average media sentiment score of 0.07 beat Nemaura Medical's score of 0.00 indicating that Sintx Technologies is being referred to more favorably in the media.
Nemaura Medical has a consensus price target of $2.50, indicating a potential upside of 5,455.56%. Given Nemaura Medical's stronger consensus rating and higher probable upside, analysts plainly believe Nemaura Medical is more favorable than Sintx Technologies.
Sintx Technologies has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.
Summary
Sintx Technologies beats Nemaura Medical on 10 of the 18 factors compared between the two stocks.
Get Sintx Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SINT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sintx Technologies Competitors List
Related Companies and Tools
